Therapy for ocular toxoplasmosis

Ocular Immunology and Inflammation

Volumn 19, Issue 5, 2011, Pages 314-320

  De La Torre, Alejandra ^a   Stanford, Miles ^b   Curi, Andre ^c   Jaffe, Glenn J ^d   Gomez Marin, Jorge E ^a  

^a Centro de Investigaciones Biomédicas   (Colombia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

Antibiotics; Ocular toxoplasmosis; Recurrences; Steroids; Therapy; Treatment; Uveitis

Indexed keywords

ANTIINFECTIVE AGENT; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLINIC ACID; MINOCYCLINE; PREDNISOLONE; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN; SULFADIAZINE; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM;

ANTIMICROBIAL THERAPY; CHORIORETINITIS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CRYOTHERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; LASER COAGULATION; MEDICAL LITERATURE; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; REVIEW; TOXOPLASMOSIS; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; CLINDAMYCIN; DEXAMETHASONE; FEMALE; HUMANS; MALE; OPHTHALMIC SOLUTIONS; RECURRENCE; TOXOPLASMOSIS, OCULAR; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UVEITIS;

EID: 80053636992     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.608915     Document Type: Review

References (47)

1. Arevalo JF, Belfort R, Muccioli C, Espinoza JV. Ocular toxo-plasmosis in the developing world. Int Ophthalmol Clin. 2010;50(2):57-69
2. de-la-Torre A, López-Castillo CA, Rueda JC, Mantilla RD, Gómez-Marín JE, Anaya JM. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin Exp Ophthalmol. 2009 Jul;37(5):458-466.
3. Holland G, Lewis K. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(6):102-114. (Pubitemid 34722718)
4. Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724-726.
5. Gilbert RE, Harden M, Stanford M. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Systematic Rev. 2002, Issue 1. Art. No.: CD002218. DOI: 10.1002/14651858.CD002218.
6. Vedula SS, Nguyen QD. Corticosteroidsfor ocular toxoplas-mosis. Cochrane Database Systematic Rev. 2008, Issue 4. Art. No.: CD007417. DOI: 10.1002/14651858.CD007417.
7. Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134(1):41-46. (Pubitemid 34722708)
8. Acers TE. Toxoplasmicretinochoroiditis: a double-blind therapeutic study. Arch Ophthalmol. 1964;71:58-62.
9. Belfort R, Muccioli C, Silveira C. Trimetoprim and sulfame-toxazol for the prevention of toxoplasmicretinochoroiditis recurrences. Invest Ophthalmol Vis Sci. 2000;41:595.
10. Perkins ES, Smith CH, Schoeld PB. Treatment of uveitis withpyrimethamine (Daraprim). Br J Ophthalmol. 1956;40:577-586.
11. Gilbert RE, Freeman K, Lago EG, et al.; The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Ocular Sequelae of Congenital Toxoplasmosis in Brazil Compared with Europe. PLoSNeglTropDis 2008;2:e277.
12. Gallego C, Saavedra-Matiz C, Gómez-Marín JE. Direct genotyping of animal and human isolates of Toxoplasma gondii from Colombia (South America). Acta Tropica. 2006,97:161-167. (Pubitemid 43087749)
13. Garweg JG, Ventura AC, Halberstadt M, et al. Specifc antibody levels in the aqueous humor and serum of two distinct populations of patients with ocular toxoplasmosis. Int J Med Microbiol. 2005;295(4):287-295. (Pubitemid 41020802)
14. Sauer A, de la Torre A, Gomez-Marin J, Bourcier T, Garweg J, Speeg-Schatz C, Candolf E. Prevention of retinochoroiditis in congenital toxoplasmosis: Europe versus South America. Pediatr Infect Dis J. 2011;30:601-603.
15. Stanford MR, Gilbert RE. Treating ocular toxoplasmosis: current evidence. Mem Inst Oswaldo Cruz. 2009;104(2):312-315.
16. Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134-141. Epub 2010 Aug 12.
17. Lasave AF, Díaz-Llopis M, Muccioli C, Belfort R Jr, Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmicretinochoroiditis at twenty-four months. Ophthalmology. 2010;117(9):1831-1838. Epub 2010 May 14.
18. Winterhalter S, Severing K, Stammen J, Maier AK, Godehardt E, Joussen AM. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1187-1192. Epub 2010 May 2.
19. Yazici A, Ozdal PC, Taskintuna I, Kavuncu S, Koklu G. Trimethoprim/sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. Ocul Immunol Infamm. 2009 Jul-Aug;17(4):289-291
20. The SYROCOT Study Group, Thiebaut R, Leproust S, Chene G, Gilbert RE. Effectiveness of prenatal treatment for congenital toxoplasmosis: a metaanalysis of individual patients' data. Lancet. 2007;369:115-122.
21. Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F, Franck J. Risk factors for retinochoroiditis during the frst 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J. 2008;27:27-32.
22. Freeman K, Tan HK, Prusa A, et al.; European Multicentre Study on Congenital Toxoplasmosis. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics. 2008;121(5):e1215-e1222.
23. Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the frst year of life. Am J Ophthalmol. 2008;146:375-384.
24. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004;113(6):1567-1572. (Pubitemid 38697960)
25. Lahmar I, Guinard M, Sauer A, et al. Murine neonatal infection provides an effcient model for congenital ocular toxo-plasmosis. Exp Parasitol. 2010;124:190-196.
26. Andrade GM, Vasconcelos-Santos DV, Carellos EV, et al. Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy. J Pediatr (Rio J). 2010;86:85-88.
27. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30:481-501. (Pubitemid 46873074)
28. Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517-523 (Pubitemid 23109806)
29. de-la-Torre A, Rios-Cadavid AC, Cardozo-García CM, Gomez-Marín JE. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol. 2009;93:1001-1004.
30. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009;104:320-344.
31. Holland GN, Engstrom R, Glasgow BJ, et al. Ocular toxo-plasmosis in patients with the acquired immunodefciency syndrome. Am J Ophthalmol. 1988;106:653-667. (Pubitemid 19009919)
32. Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplas-mosis misdiagnosed as cytomegalovirus retinopathy in immu-nocompromised patients. Ophthalmology. 1994;101:499-507. (Pubitemid 24100574)
33. Cochereau-Massin I, Le-Hoang P, Lautier-Frau M, et al. Ocular toxoplasmosis in human immunodefciency virus infected patients. Am J Ophthalmol. 1992;114:130-135.
34. Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63-86.
35. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991;164:170-171.
36. Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immu-nocompetent patients. Ophthalmology. 1999;106:148-153.
37. Lopez JS, De Smet MD, Masur H, et al. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodefciency syndrome. Am J Ophthalmol. 1992;113(3):331-333.
38. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vspyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002; 134(1):34-40. (Pubitemid 34722707)
39. Silveira C, Vallochi AL, Rodrigues da Silva U, et al. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol. 2011;95(3):396-400.
40. O'Connor GR, Frenkel JK. [Editorial] Dangers of steroid treatment in toxoplasmosis: periocular injections and systemic therapy. Arch Ophthalmol. 1976;94 (2):213.
41. Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxo-plasmosis. Am J Ophthalmol. 1981;92:497-503.
42. Dorangeon PH, Marx-Chemla C, Quereux C, et al. [The risks of pyrimethamine-sulfadoxine combination in the prena-taltreatment of toxoplasmosis]. J Gynecol Obstet Biol Reprod (Paris). 1992;21:549-556.
43. Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;11:1876-1882.
44. Kishore K, Conway MD, Peyman GA. Intravitreal clindamy-cin and dexamethasone for toxoplasmicretinochoroiditis. Ophthalmic Surg Lasers. 2001;32(3):183-192.
45. Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother. 1995;39:1530-1537.
46. Peyman GA, Lee PJ, Seal D. Endophthalmitis Diagnosis and Management. London: Taylor & Francis; 2004: 81-100.
47. Miro JM, Lopez JC, Podzamczer D, et al. GESIDA 04/98 Study Group.Discontinuation of primary and secondary Toxoplasma gondiiprophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiret-roviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006;43(1):79-89. (Pubitemid 43939080)